|
|
 Previous Article | Table of Contents | Next Article 
Blood, 15 December 2000, Vol. 96, No. 13, pp. 4091-4095
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
Serum level of soluble urokinase-type plasminogen activator
receptor is a strong and independent predictor of survival in human
immunodeficiency virus infection
Nicolai Sidenius,
Cornelis F. M. Sier,
Henrik Ullum,
Bente Klarlund Pedersen,
Alessandro Cozzi Lepri,
Francesco Blasi, and
Jesper Eugen-Olsen
From the Department of Molecular Pathology and
Medicine, Molecular Genetics Unit, DIBIT, San Raffaele Scientific
Institute, Milan, Italy; the Department of Infectious Diseases,
Rigshospitalet, Copenhagen; the Department of Infectious Diseases and
Clinical Research Unit, Hvidovre Hospital, Denmark; and the Royal Free
Centre for HIV Medicine and the Department of Primary Care and
Population Sciences, Royal Free and University College Medical School,
University College London, London, United Kingdom.
Human immunodeficiency virus-1 (HIV-1) infection has been shown to
result in up-regulation of the urokinase-type plasminogen activator
receptor (uPAR/CD87) on leukocytes in vitro and in vivo. The objective of this study was to investigate whether this
up-regulation is paralleled by higher serum levels of soluble uPAR
(suPAR) in patients with advanced HIV-1 disease and whether the serum
level of suPAR is predictive of clinical outcome. Using an
enzyme-linked immunosorbent assay, the level of suPAR was measured
retrospectively in serum samples from 314 patients with HIV-1
infection. By Kaplan-Meier and Cox regression analyses, the serum suPAR
levels were correlated to survival with AIDS-related death as the end
point. High levels of serum suPAR (greater than median) were associated
with poor overall survival, and Kaplan-Meier analysis on patients
stratified by suPAR level demonstrated a continuous increase in
mortality rates with higher suPAR levels. After adjustment for accepted prognostic markers including Centers for Disease Control and
Prevention-defined clinical stages, CD4 counts, viral load,
 2-microglobulin, and agethe prognostic strength of suPAR remained
highly significant, indicating that the serum suPAR level is a novel,
strong, and independent predictor of survival in HIV-1 infection. This
report is the first to demonstrate an important association between the plasminogen activator system and disease progression in HIV-1 infection.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
Y.-J. Park, G. Liu, Y. Tsuruta, E. Lorne, and E. Abraham
Participation of the urokinase receptor in neutrophil efferocytosis
Blood,
July 23, 2009;
114(4):
860 - 870.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Alfano, S. A. Mariani, C. Elia, R. Pardi, F. Blasi, and G. Poli
Ligand-engaged urokinase-type plasminogen activator receptor and activation of the CD11b/CD18 integrin inhibit late events of HIV expression in monocytic cells
Blood,
February 19, 2009;
113(8):
1699 - 1709.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. F. Kingsmore, N. Kennedy, H. L. Halliday, J. C. Van Velkinburgh, S. Zhong, V. Gabriel, J. Grant, W. D. Beavis, V. T. Tchernev, L. Perlee, et al.
Identification of Diagnostic Biomarkers for Infection in Premature Neonates
Mol. Cell. Proteomics,
October 1, 2008;
7(10):
1863 - 1875.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Elia, E. Cassol, N. Sidenius, F. Blasi, A. Castagna, G. Poli, and M. Alfano
Inhibition of HIV replication by the plasminogen activator is dependent on vitronectin-mediated cell adhesion
J. Leukoc. Biol.,
November 1, 2007;
82(5):
1212 - 1220.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Kofoed, U. V. Schneider, T. Scheel, O. Andersen, and J. Eugen-Olsen
Development and Validation of a Multiplex Add-On Assay for Sepsis Biomarkers Using xMAP Technology
Clin. Chem.,
July 1, 2006;
52(7):
1284 - 1293.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Selleri, N. Montuori, P. Ricci, V. Visconte, M. V. Carriero, N. Sidenius, B. Serio, F. Blasi, B. Rotoli, G. Rossi, et al.
Involvement of the urokinase-type plasminogen activator receptor in hematopoietic stem cell mobilization
Blood,
March 1, 2005;
105(5):
2198 - 2205.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-W. Qiang, L. Yao, G. Tosato, and S. Rudikoff
Insulin-like growth factor I induces migration and invasion of human multiple myeloma cells
Blood,
January 1, 2004;
103(1):
301 - 308.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Alfano, N. Sidenius, F. Blasi, and G. Poli
The role of urokinase-type plasminogen activator (uPA)/uPA receptor in HIV-1 infection
J. Leukoc. Biol.,
November 1, 2003;
74(5):
750 - 756.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Coleman and J. L. Benach
The Urokinase Receptor Can Be Induced by Borrelia burgdorferi through Receptors of the Innate Immune System
Infect. Immun.,
October 1, 2003;
71(10):
5556 - 5564.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Alfano, N. Sidenius, B. Panzeri, F. Blasi, and G. Poli
Urokinase-urokinase receptor interaction mediates an inhibitory signal for HIV-1 replication
PNAS,
June 25, 2002;
99(13):
8862 - 8867.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Resnati, I. Pallavicini, J. M. Wang, J. Oppenheim, C. N. Serhan, M. Romano, and F. Blasi
The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R
PNAS,
January 24, 2002;
(2002)
22652999.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Resnati, I. Pallavicini, J. M. Wang, J. Oppenheim, C. N. Serhan, M. Romano, and F. Blasi
The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R
PNAS,
February 5, 2002;
99(3):
1359 - 1364.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
